Literature DB >> 29273581

Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications.

Paul M Ridker1.   

Abstract

Keywords:  atherosclerosis; canakinumab; evolocumab; mortality; prevention and control; randomized controlled trials as topic

Mesh：

Substances：

Year:  2017        PMID： 29273581     DOI： 10.1161/CIRCULATIONAHA.117.033254

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  8 in total

1.  Statins and C-reactive protein: in silico evidence on direct interaction.

Authors:  Neda Shakour; Massimiliano Ruscica; Farzin Hadizadeh; Cesare Cirtori; Maciej Banach; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Arch Med Sci       Date:  2020-11-02       Impact factor: 3.318

2.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.

Authors:  Aruna D Pradhan; Aaron W Aday; Lynda M Rose; Paul M Ridker
Journal:  Circulation       Date:  2018-05-01       Impact factor: 29.690

Review 3.  Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond.

Authors:  Aaron W Aday; Paul M Ridker
Journal:  Front Cardiovasc Med       Date:  2018-06-05

Review 4.  NLRP3 Inflammasome Signaling as a Link Between HIV-1 Infection and Atherosclerotic Cardiovascular Disease.

Authors:  Caroline Mullis; Talia H Swartz
Journal:  Front Cardiovasc Med       Date:  2020-06-11

5.  Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque.

Authors:  Marcin Basiak; Michal Kosowski; Marcin Hachula; Boguslaw Okopien
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-27

6.  Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque.

Authors:  Michał Kosowski; Marcin Basiak; Marcin Hachuła; Bogusław Okopień
Journal:  Medicina (Kaunas)       Date:  2022-07-21       Impact factor: 2.948

Review 7.  Pleiotropic Effects of PCSK-9 Inhibitors.

Authors:  Marcin Basiak; Michał Kosowski; Marcin Cyrnek; Łukasz Bułdak; Mateusz Maligłówka; Grzegorz Machnik; Bogusław Okopień
Journal:  Int J Mol Sci       Date:  2021-03-19       Impact factor: 5.923

Review 8.  Insight into the Evolving Role of PCSK9.

Authors:  Mateusz Maligłówka; Michał Kosowski; Marcin Hachuła; Marcin Cyrnek; Łukasz Bułdak; Marcin Basiak; Aleksandra Bołdys; Grzegorz Machnik; Rafał Jakub Bułdak; Bogusław Okopień
Journal:  Metabolites       Date:  2022-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.